Morgan Stanley predicts it will take 4 to 9 months to vaccinate the rest of the US after first responders and vulnerable people
COVID-19vaccines, one made by Moderna, another by Pfizer and BioNTech, announced promising results from their Phase 3 trials this week.
- Moderna announced that its
vaccinewas 94.5% effective on Monday, and Pfizer/BioNTech announced that their vaccine was 95% effective on Wednesday.
- Assuming that one or both of the vaccines receive emergency approval from the FDA, first responders and vulnerable populations will receive vaccines through March, a new analysis from
- After that, the rest of the US population will begin to be vaccinated, a process that Morgan Stanley predicts will take four to nine months.
After vaccinating first responders and vulnerable populations like the elderly, it will take four to nine months to vaccinate the rest of the US, Morgan Stanley predicted in a report published Friday.
Vaccinating the general population will likely last from spring of 2021 to winter of 2021, Morgan Stanley analysts forecasted.To estimate the amount of time it will take to vaccinate the general population, the analysts looked at major pharmacy
Read more: Pharmacies, doctor's offices and hospitals are gearing up to give coronavirus vaccines to millions of Americans. Here's how they're preparing and how much they stand to profit along the way.The prediction comes after promising results in November from two COVID-19 vaccine candidates made by pharmaceutical companies Pfizer and its partner BioNTech, and Moderna. On Monday, Moderna announced that its vaccine was 94.5% effective against COVID-19, and on Wednesday, Pfizer and BioNTech announced that their vaccine was 95% effective.
Neither has been approved for use by the Food and Drug Administration, and the results of the vaccine trials have yet to be peer reviewed. But Pfizer and BioNTech said that they were filing their COVID-19 vaccine for emergency approval from the FDA on Friday, and Moderna has said it will do the same in the coming days.CVS has 60,000 pharmacy technicians employed, according to Morgan Stanley, and plans on hiring an additional 10,000 to cope with flu season and increased COVID-19 cases, the company announced in October. Morgan Stanley analysts also estimate that the company could make $763 million to $1.5 billion EBIT (earnings before interest and taxes) from administering COVID-19 vaccines.
- IMF projects 11.5% growth rate for India in 2021, only major economy to record double digit growth
- Connaught Place to remain shut as farmers' tractor parade turns violent
- After violent clashes with police, farmers swarm Red Fort
- DMRC closed entry and exit gates of yellow, green, violet and blue lines in surge of farmers protest
- Delhi Police fires tear-gas shells on farmers near Akshardham temple and Sanjay Gandhi Transport Nagar